Response to letter commenting on ʻindications for hyperthermic intraperitoneal chemotherapy (Hipec) with cytoreductive surgery: a systematic reviewʼ

We thank M. Soucisse et al. for their informed reply and perspective related to the treatment of rare peritoneal surface malignancies, such as pseudomyxoma peritonei and mesothelioma. While we appreciate that level one evidence may be difficult or impossible to generate for rare cancers, the Program in Evidence Based Care has defined a rigorously developed process to systematically search for, identify and analyse primary study evidence. The process is not meant to provide a complete summary of all the available evidence but to identify studies that are relevant for the formulation of recommendations.

Lascia un commento